Clinical Trial Update: Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating anakinra (ANAKINRA) for systemic-onset juvenile idiopathic arthritis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic-onset Juvenile Idiopathic Arthritis

Drugs mentioned

• Anakinra (anakinra)

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Systemic-Onset Juvenile Idiopathic Arthritis | Phase 2, Phase 3 | Status: COMPLETED